Development of doxorubicin resistant rat prostate cancer cell lines

T. S. Replogle-Schwab, E. D. Schwab, K. J. Pienta

Research output: Contribution to journalArticle

Abstract

Background: One possible mechanism of chemotherapeutic resistance in patients with metastatic prostate cancer is the overexpression of P-glycoprotein. Additional tumor models are necessary to study this phenomenon. Materials and Methods. Doxorubicin resistant rat prostate cancer cell lines were developed by increasing doxorubicin levels in cell culture. Results: The MDR lines (AT3B-1, AT3B-2, MLLB-1, and MLLB-2) were more resistant to vinblastine compared to controls. When P-glycoprotein was blocked the AT3 MDR lines demonstrated efflux activity. Injection of AT3 MDR lines into rats followed by doxorubicin treatment produced larger tumors compared to the parental controls. Conclusions: MDR rat prostate cancer cells were developed. AT3B-1 and AT3B-2 cell lines have drug efflux pump ability, whereas the MLLB-1 and MLLB-2 may not, suggesting alternative key mechanisms other than P-glycoprotein overexpression. These new cell lines are being used to study chemotherapy resistance in prostate cancer.

Original languageEnglish (US)
Pages (from-to)4535-4538
Number of pages4
JournalAnticancer research
Volume17
Issue number6 D
StatePublished - Nov 1 1997
Externally publishedYes

Keywords

  • AT3
  • MAT-Ly-Lu
  • Multidrug resistance
  • P-glycoprotein

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Development of doxorubicin resistant rat prostate cancer cell lines'. Together they form a unique fingerprint.

  • Cite this

    Replogle-Schwab, T. S., Schwab, E. D., & Pienta, K. J. (1997). Development of doxorubicin resistant rat prostate cancer cell lines. Anticancer research, 17(6 D), 4535-4538.